Section
Vaccination against SARS-CoV-2 during pregnancy significantly lowers risks of severe maternal COVID-19, hospitalization, critical care admission, and preterm birth across variant periods, underscoring its safety and efficacy for maternal an
The French GR2 prospective study reveals that while 91% of pregnancies in systemic sclerosis result in livebirths, patients face significantly higher risks of pre-eclampsia, fetal growth restriction, and severe postpartum hemorrhage, with n
Oral progestagens reduce overall pain and dysmenorrhoea in endometriosis, but comparative benefits over other hormonal therapies remain uncertain.
Evidence suggests simple hysterectomy with pelvic lymphadenectomy may offer similar survival outcomes to radical hysterectomy in early-stage cervical cancer, with fewer adverse events and better short-term quality of life.
A clear, evidence-based summary of the 2025 Cochrane review on immediate/early skin-to-skin contact (SSC), its impact on breastfeeding and newborn physiology, gaps in maternal outcomes, and practical recommendations for clinical implementat
Randomised trials show breast surgery improves local disease control but not overall survival in de novo metastatic breast cancer.
A large network meta‑analysis confirms HPV vaccines effectively reduce CIN2+ and anogenital warts, with no major safety concerns.
This review synthesizes recent randomized controlled trials and meta-analyses on calcium supplementation during pregnancy, evaluating its effectiveness in preventing hypertensive disorders such as pre-eclampsia and related maternal and neon
This review synthesizes data on mifepristone availability at community pharmacies in BC, highlighting geographic coverage, dispensing gaps, and disparities influencing timely access to medication abortion.
This review synthesizes evidence linking adherence to the Planetary Health Diet with reduced risks of myocardial infarction, type 2 diabetes, and improved weight management in women post-gestational diabetes, highlighting BMI’s mediat
A randomized trial of 20,330 girls 12–16 years shows one dose of bivalent or nonavalent HPV vaccine prevents persistent HPV16/18 infection as effectively as two doses over 5 years, with high effectiveness and no safety signals.
Genetic predisposition to preeclampsia and gestational hypertension is associated with higher risk of later-life cardiovascular disease; polygenic risk amplifies this risk, while obstetric history improves risk stratification beyond PRSs al
Elinzanetant, approved in the UK in July 2025 and by the FDA in October 2025, is the first non-hormonal NK1 and NK3 receptor antagonist for moderate-to-severe menopausal vasomotor symptoms, demonstrated effective and safe in pivotal phase 2
OASIS‑3 evaluated once‑daily oral elinzanetant 120 mg vs placebo for 52 weeks in postmenopausal women with moderate–severe vasomotor symptoms. At 12 weeks elinzanetant reduced daily moderate–severe VMS frequency by a least‑squares mean diff
A randomized phase 3b trial found no infant safety signals attributable to in-utero exposure to the dapivirine vaginal ring or oral tenofovir–emtricitabine PrEP over 12 months of follow-up, supporting use of both options for HIV prevention
A Swedish nationwide cohort (n≈2.1M) found small but measurable variation in breast cancer risk by hormonal contraceptive formulation—higher with desogestrel/etonogestrel products and lower with levonorgestrel-containing devices; absolute e
The VENUSCANCER secondary analysis of 275,792 records from 103 population-based registries reveals wide global variation in stage at diagnosis, concordance with guideline-recommended initial treatments, and time to treatment for breast, cer
A multifaceted national preterm birth prevention programme in Australia was associated with a modest national decrease in late preterm births and, after a hospital collaborative, a substantial reduction in early‑term births in participating
A multicenter phase II trial of HMI-115, a human monoclonal antibody against the prolactin receptor, showed dose-dependent reductions in endometriosis-associated pain and preserved ovarian function, supporting larger Phase III evaluation.
A 5-year follow-up study in El Salvador demonstrates that primary HPV screen-and-treat significantly reduces CIN2+ detection and HPV positivity compared to cytology, supporting extended screening intervals in low-resource settings.
